News
Sanofi to buy US biopharma group Blueprint for up to US$9.5 billion
PARIS] France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year,
In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...
Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...
Its immunology drug Dupixent is approved to ... Unlike many unprofitable biotech companies, Regeneron was in the “green” and generated $4.3 billion in net income in 2022.
One takeaway from the ongoing biotech IPO drought is that companies should have at least ... development of a pipeline of inflammation and immunology (I&I) drugs, including a lead program that ...
With the new fund, Arch plans to invest in companies addressing infectious disease, mental health, immunology ... remains bullish on opportunity in the biotech market. "All the fundamental ...
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...
China is teeming with promising science in areas such as oncology and immunology ... comes not only from other VC firms or even biotech companies. It’s coming from big pharma, he said.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback